Sharing Decisions in Cancer Care Important but Difficult to Implement
the Cancer Therapy Advisor take:
Medical specialists recognized the importance of sharing the decision-making process with patients but found it to be difficult to implement in practice, according to an article published online in the journal The Oncologist.
In this study, medical specialists were interviewed and a focus group was established. In the focus group, the investigators analyzed the specialists’ opinions regarding shared decision-making, patient involvement, and their applicability in the context of patients with glioblastoma.
Results showed health care professionals considered patient involvement in decision-making to be important; however, most did not follow through with its elements. Furthermore, specialists did not consider stopping treatment to be equal to continuing treatment.
The authors identified preferences of both patients and medical specialists for starting or continuing treatment and specialists’ assumptions of knowing the patients’ desires as being the major barriers to shared decision-making.
The study suggests training be made available for physicians in order to improve communication and patient involvement in the decision-making process, especially for patients with glioblastoma.
Medical specialists recognized the importance of sharing the decision-making process with patients but found it to be difficult to implement in practice.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC
- Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC
- Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
- Assays May Help Researchers Discover Factors Underlying Immunotherapy Response
- Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer